Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408: 307-310. 10.1038/35042675.
Article
CAS
PubMed
Google Scholar
Momand J, Jung D, Wilczynski S, Niland J: The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26: 3453-3459. 10.1093/nar/26.15.3453.
Article
CAS
PubMed
PubMed Central
Google Scholar
Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992, 358: 80-83. 10.1038/358080a0.
Article
CAS
PubMed
Google Scholar
Pilotti S, Della TG, Lavarino C, Di PS, Sozzi G, Minoletti F, et al: Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol. 1997, 181: 14-24. 10.1002/(SICI)1096-9896(199701)181:1<14::AID-PATH730>3.0.CO;2-O.
Article
CAS
PubMed
Google Scholar
Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O: MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst. 1994, 86: 1297-1302. 10.1093/jnci/86.17.1297.
Article
CAS
PubMed
Google Scholar
Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, Forus A: Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene. 2003, 22: 5358-5361. 10.1038/sj.onc.1206671.
Article
CAS
PubMed
Google Scholar
Helman LJ, Meltzer P: Mechanisms of sarcoma development. Nat Rev Cancer. 2003, 3: 685-694. 10.1038/nrc1168.
Article
CAS
PubMed
Google Scholar
Brennan MF, Singer S, Maki RG, O'Sullivan B: Soft tissue sarcoma. Cancer Principles and Practice of Oncology. Edited by: DeVita Jr VT, Hellman S, Rosenberg SA. 2005, Philadelphia: Lippincott Williams and Wilkins, 1581-1637. 7
Google Scholar
Malawer MM, Helman LJ, O'Sullivan B: Bone Sarcoma. Cancer Principles and Practice of Oncology. Edited by: DeVita Jr VT, Hellman S, Maki RG, O'Sullivan B. 2005, Philadelphia: Lippincott Williams and Wilkins, 2: 1638-7
Google Scholar
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004, 303: 844-848. 10.1126/science.1092472.
Article
CAS
PubMed
Google Scholar
Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA. 2006, 103: 1888-1893. 10.1073/pnas.0507493103.
Article
CAS
PubMed
PubMed Central
Google Scholar
Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de FM, Castano E, et al: MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006, 107: 4109-4114. 10.1182/blood-2005-08-3273.
Article
CAS
PubMed
Google Scholar
Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A, et al: Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006, 107: 4122-4129. 10.1182/blood-2005-11-4465.
Article
CAS
PubMed
Google Scholar
Jiang M, Pabla N, Murphy RF, Yang T, Yin XM, Degenhardt K, et al: Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J Biol Chem. 2007, 282: 2636-2645.
Article
CAS
PubMed
Google Scholar
Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW: Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006, 66: 3169-3176. 10.1158/0008-5472.CAN-05-3832.
Article
CAS
PubMed
Google Scholar
Wade M, Wong ET, Tang M, Stommel JM, Wahl GM: Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem. 2006, 281: 33036-33044. 10.1074/jbc.M605405200.
Article
CAS
PubMed
Google Scholar
Popowicz GM, Czarna A, Rothweiler U, Sszwagierczak A, Krajewski M, Weber L, et al: Molecular Basis for the Inhibition of p53 by Mdmx. Cell Cycle. 2007, 6-
Google Scholar
Freedman DA, Wu L, Levine AJ: Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999, 55: 96-107. 10.1007/s000180050273.
Article
CAS
PubMed
Google Scholar
Vassilev LT: MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007, 13: 23-31. 10.1016/j.molmed.2006.11.002.
Article
CAS
PubMed
Google Scholar
Muller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O: Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007, 121: 199-205. 10.1002/ijc.22643.
Article
CAS
PubMed
Google Scholar
Cao C, Shinohara ET, Subhawong TK, Geng L, Woon KK, Albert JM, et al: Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Molecular Cancer Therapeutics. 2006, 5: 411-417. 10.1158/1535-7163.MCT-05-0356.
Article
CAS
PubMed
Google Scholar
Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, et al: MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006, 5: 2358-2365. 10.1158/1535-7163.MCT-06-0305.
Article
CAS
PubMed
Google Scholar
Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, et al: Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005, 106: 3609-3617. 10.1182/blood-2005-04-1489.
Article
PubMed
Google Scholar
Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, et al: Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res. 2007, 13: 3380-3387. 10.1158/1078-0432.CCR-06-2581.
Article
CAS
PubMed
Google Scholar
Tabe Y, Sebasigari D, Jin L, Rudelius M, vies-Hill T, Miyake K, et al: MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009, 15: 933-942. 10.1158/1078-0432.CCR-08-0399.
Article
CAS
PubMed
Google Scholar
Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, et al: Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J Cancer Res Clin Oncol. 2010
Google Scholar
Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT: Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005, 65: 1918-1924. 10.1158/0008-5472.CAN-04-3576.
Article
CAS
PubMed
Google Scholar
Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, et al: Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res. 2009, 15: 4077-4084. 10.1158/1078-0432.CCR-08-2955.
Article
CAS
PubMed
Google Scholar
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004, 56: 185-229. 10.1124/pr.56.2.6.
Article
CAS
PubMed
Google Scholar
Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003, 22: 7265-7279. 10.1038/sj.onc.1206933.
Article
CAS
PubMed
Google Scholar
Perego P, Corna E, De CM, Gatti L, Polizzi D, Pratesi G, et al: Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem. 2001, 8: 31-37.
Article
CAS
PubMed
Google Scholar
Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, et al: Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer. 1999, 24: 30-41. 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P.
Article
CAS
PubMed
Google Scholar
Roberts WM, Douglass EC, Peiper SC, Houghton PJ, Look AT: Amplification of the gli gene in childhood sarcomas. Cancer Res. 1989, 49: 5407-5413.
CAS
PubMed
Google Scholar
Berg M, Agesen TH, Thiis-Evensen E, Merok MA, Teixeira MR, Vatn MH, et al: Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Mol Cancer. 2010, 9: 100-10.1186/1476-4598-9-100.
Article
PubMed
PubMed Central
Google Scholar
Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM: Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer. 1991, 27: 897-900. 10.1016/0277-5379(91)90142-Z.
Article
CAS
PubMed
Google Scholar
Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv E,nzyme Regul. 1984, 22: 27-55.
Article
CAS
Google Scholar
Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006, 58: 621-681. 10.1124/pr.58.3.10.
Article
CAS
PubMed
Google Scholar
Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ: Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA. 1987, 84: 7716-7719. 10.1073/pnas.84.21.7716.
Article
CAS
PubMed
PubMed Central
Google Scholar
Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, et al: Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992, 52: 2243-2247.
CAS
PubMed
Google Scholar
Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G: Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002, 3: 655-664. 10.1016/S1470-2045(02)00899-9.
Article
CAS
PubMed
Google Scholar
Andreassen A, Oyjord T, Hovig E, Holm R, Florenes VA, Nesland JM, et al: p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 1993, 53: 468-471.
CAS
PubMed
Google Scholar
Korotchkina LG, Demidenko ZN, Gudkov AV, Blagosklonny MV: Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle. 2009, 8: 3777-3781. 10.4161/cc.8.22.10121.
Article
CAS
PubMed
Google Scholar
Toledo F, Wahl GM: MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007, 39: 1476-1482. 10.1016/j.biocel.2007.03.022.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J: MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem. 2006, 281: 33030-33035. 10.1074/jbc.C600147200.
Article
CAS
PubMed
Google Scholar
Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F: E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene. 2008, 27: 5303-5314. 10.1038/onc.2008.164.
Article
CAS
PubMed
Google Scholar
Lau LM, Nugent JK, Zhao X, Irwin MS: HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene. 2008, 27: 997-1003. 10.1038/sj.onc.1210707.
Article
CAS
PubMed
Google Scholar
Michaelis M, Rothweiler F, Klassert D, von DA, Weber K, Fehse B, et al: Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res. 2009, 69: 416-421. 10.1158/0008-5472.CAN-08-1856.
Article
CAS
PubMed
Google Scholar
Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK: Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene. 2007, 26: 3473-3481. 10.1038/sj.onc.1210136.
Article
CAS
PubMed
Google Scholar
Peirce SK, Findley HW: The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol. 2009, 34: 1395-1402.
CAS
PubMed
Google Scholar
Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 2002, 1587: 164-173.
Article
CAS
PubMed
Google Scholar
DeGregori J, Kowalik T, Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis-and G1/S-regulatory genes. Mol Cell Biol. 1995, 15: 4215-4224.
Article
CAS
PubMed
PubMed Central
Google Scholar
Aslanian A, Iaquinta PJ, Verona R, Lees JA: Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev. 2004, 18: 1413-1422. 10.1101/gad.1196704.
Article
CAS
PubMed
PubMed Central
Google Scholar
Francoz S, Froment P, Bogaerts S, De CS, Maetens M, Doumont G, et al: Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA. 2006, 103: 3232-3237. 10.1073/pnas.0508476103.
Article
CAS
PubMed
PubMed Central
Google Scholar
Maguire M, Nield PC, Devling T, Jenkins RE, Park BK, Polanski R, et al: MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res. 2008, 68: 3232-3242. 10.1158/0008-5472.CAN-07-5271.
Article
CAS
PubMed
PubMed Central
Google Scholar